Generer rapport
Biomérieux Denmark Aps
Lautruphøj 1-3, 2750 Ballerup, CVR 10062462
Virksomhedsform
Anpartsselskab
Etableret
2001
Størrelse
Mikro
Ansatte
9
Omsætning
65
MDKK
Bruttofortj.
12
MDKK
Primært resultat (EBIT)
4.635.257
DKK
Årets resultat
3.632.278
DKK
Egenkapital
14
MDKK
annonce
Flere nøgletal og analyser?
Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!
Rang Årets resultat
Rang i branche
2.424/34.867
"Top 10%"
Rang i Danmark
25.521/343.814
"Top 10%"
Direktion top 3
Bestyrelse top 3
Denis Bernard Monnaie 1 | Bestyrelsesformand |
Bertrand Playe 1 | Bestyrelsesmedlem |
Vincent Bruno Marciniak 1 | Bestyrelsesmedlem |
Legale ejere top 3
100% | bioMerieux SA | FR |
Tegningsregler
Selskabet tegnes af to medlemmer af bestyrelsen i forening eller af en direktør.
Stamoplysninger baseret på CVR
Navn | Biomérieux Denmark Aps |
CVR | 10062462 |
Adresse | Lautruphøj 1-3, 2750 Ballerup |
Branche | Engroshandel med læge- og hospitalsartikler [464620] |
Etableret | 19-01-2001 (23 år) |
Første regnskabsperiode | 19-01-2001 til 31-12-2001 |
Virksomhedsform | Anpartsselskab |
Antal ansatte | 9 (årsværk:9) |
Reklamebeskyttelse | Nej |
Revisor | Ey Godkendt Revisionspartnerselskab siden 10-10-2014 |
Regnskabsperiode | 01-01 til 31-12 |
Selskabskapital | 500.000 DKK 125.000 DKK (19-01-2001 - 20-12-2001) |
Vedtægter seneste | 29-04-2014 |
Medlem af brancherne
- Engroshandel med læge- og hospitalsartiklerNACE6 indeholdende 376 virk.
- Engroshandel med husholdningsartiklerNACE3 indeholdende 6.325 virk.
- Engroshandel undtagen med motorkøretøjer og motorcyklerNACE2 indeholdende 24.347 virk.
- Engroshandel og detailhandel, reparation af motorkøretøjer og motorcyklerNACE1 indeholdende 75.206 virk.
Formål
Selskabets formål er produktion, køb, salg og marketing af diagnostikudstyr og hermed beslægtede produkter samt anden i forbindelse med disse formål stående virksomhed. Selskabets formål er herudover at eje kapitalandele i andre selskaber.
Regnskab
2022 | 2021 | 2020 | |
---|---|---|---|
Valuta/enhed | 000' DKK | 000' DKK | 000' DKK |
Omsætning | 65.119 -16% | 77.639 -100% | 68.283.096 +104.788% |
Bruttofortjeneste | 12.445 -16% | 14.746 -100% | 12.757.089 +112.179% |
Årets resultat | 3.632 -27% | 4.966 -100% | 3.342.442 +128.604% |
Egenkapital | 13.672 +11% | 12.274 -100% | 9.543.941 +113.033% |
Balance | 25.341 -12% | 28.656 -100% | 26.713.052 +109.375% |
Ledelsesberetning
The Company's principal activities
BIOMÉRIEUX DENMARK ApS is an in-vitro diagnostics company within the bioMérieux S.A. Group.
Development in activities and financial matters
The Company's Income Statement of the financial year 1 January 2022 - 31 December 2022 shows a result of DKK 3.632.278 and the Balance Sheet at 31 December 2022 a balance sheet total of DKK 25.340.857 and an equity of DKK 13.671.725.
Compared to the expectations for 2022 stated in the annual report for 2021 the sales has decreased by -16,2% due to slower covid situation, leading to lower reagents sales (on the clinical market -21,7%) linked to the pandemic in molecular and extraction segments.
Estimation of the future development
Next year, the sales are expected to increase by +25.2% in Clinical unit (and +7.9% in Industry) mainly thanks to the
rebound post pandemic on other ranges, as well as conversion of Covid-related business to new opportunities.
The significant increase in BGT23 versus Act 22 is indeed linked to the combination of 2 effects:
* ACT22 was below our forecasted landing for FY22 (forecast made in Sept 22 /used as basis for BGT23 growth), which increased the % gap between ACT22 and BGT23.
* Opportunities we have in terms of instruments deal in DK in 2023.
Post financial year events
After the end of the financial year, no events have occurred which may change the financial position of the entity substantially.
Development in activities and financial matters The Company's Income Statement of the financial year 1 January 2022 - 31 December 2022 shows a result of DKK 3.632.278 and the Balance Sheet at 31 December 2022 a balance sheet total of DKK 25.340.857 and an equity of DKK 13.671.725. Compared to the expectations for 2022 stated in the annual report for 2021 the sales has decreased by -16,2% due to slower covid situation, leading to lower reagents sales (on the clinical market -21,7%) linked to the pandemic in molecular and extraction segments., Development in activities and financial matters The Company's Income Statement of the financial year 1 January 2022 - 31 December 2022 shows a result of DKK 3.632.278 and the Balance Sheet at 31 December 2022 a balance sheet total of DKK 25.340.857 and an equity of DKK 13.671.725. Compared to the expectations for 2022 stated in the annual report for 2021 the sales has decreased by -16,2% due to slower covid situation, leading to lower reagents sales (on the clinical market -21,7%) linked to the pandemic in molecular and extraction segments.
Development in activities and financial matters The Company's Income Statement of the financial year 1 January 2022 - 31 December 2022 shows a result of DKK 3.632.278 and the Balance Sheet at 31 December 2022 a balance sheet total of DKK 25.340.857 and an equity of DKK 13.671.725. Compared to the expectations for 2022 stated in the annual report for 2021 the sales has decreased by -16,2% due to slower covid situation, leading to lower reagents sales (on the clinical market -21,7%) linked to the pandemic in molecular and extraction segments., Development in activities and financial matters The Company's Income Statement of the financial year 1 January 2022 - 31 December 2022 shows a result of DKK 3.632.278 and the Balance Sheet at 31 December 2022 a balance sheet total of DKK 25.340.857 and an equity of DKK 13.671.725. Compared to the expectations for 2022 stated in the annual report for 2021 the sales has decreased by -16,2% due to slower covid situation, leading to lower reagents sales (on the clinical market -21,7%) linked to the pandemic in molecular and extraction segments.
15-06-2023